Redx Pharma plc First Patient Dosed in Phase 1/2a Trial of RXC004 (9743D)

TIDMREDX

RNS Number : 9743D

Redx Pharma plc

06 February 2018

REDX PHARMA PLC

("Redx" or "the Company")

Redx Pharma Announces First Patient Dosed in Phase 1/2a Clinical Trial of its Oral Porcupine Inhibitor RXC004 in Patients with Hard to Treat Cancers

Alderley Park, February 06 2018 - Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that it has commenced its Phase 1/2a study for the Porcupine inhibitor RXC004 with the first patient having now been dosed at The Christie in Manchester.

RXC004 is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. This pathway is associated with tumorigenesis, metastasis, recurrence and resistance in cancer. RXC004 has now progressed into the dose-finding Phase 1 element of the study in patients with cancer. Once completed, the selected dose will then be used as a monotherapy in a larger number of patients with difficult to treat cancers (Phase 2a). In addition, the Company will look to explore the potential of RXC004 in combination with a PD-1 checkpoint inhibitor following the completion of the safety and tolerability phase of this first in man clinical trial.

As mentioned at the time of the publication of the Company's strategic update on 6 November 2017, Redx expects initial data from the 1a segment of this trial in H2 2018.

Iain Ross, Chairman of Redx Pharma plc, commented, "We are very excited by the potential of RXC004 to make a major difference in cancer treatment, and intend to progress RXC004 initially as a monotherapy and thereafter in combination with a (PD-1) checkpoint inhibitor through clinical development. We believe that RXC004 has great potential to treat some very challenging cancers that currently have very poor prognosis and we look forward to updating the market on our progress."

For further information, please contact:

 
Redx Pharma Plc                      T: +44 1625 
                                      469 918 
Iain Ross, Executive Chairman 
 
Cantor Fitzgerald Europe (Nominated   T: +44 20 
 Advisor & Broker)                     7894 7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)       T: +44 20 
                                      3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
FTI Consulting                       T: +44 20 
                                      3727 1000 
Simon Conway/Stephanie Cuthbert 
 

About Redx Pharma Plc

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVDFFIEIIT

(END) Dow Jones Newswires

February 06, 2018 02:00 ET (07:00 GMT)